S mooth muscle is nonstriated and involuntary muscle tissue within the walls of blood vessels including aorta, arteries, and veins, consisting of nonstriated, spindleshaped cells. Directly deriving smooth muscle cells (SMCs) from fibroblasts in vitro would provide new opportunities to study various diseases through modeling, including aortic aneurysms, atherosclerosis, and stroke, as well as facilitate tissue engineering and drug screening in personalized medicine. 1 Myocd is a master regulator of smooth muscle differentiation. [2] [3] [4] [5] Myocd was reported as inefficient for induction of smooth muscle differentiation from multipotent embryonic cells 6 although Myocd overexpression is sufficient to confer structural and functional attributes of the smooth muscle contractile phenotype. 7 A cardiac Myocd isoform containing a unique N-terminal Mef2-binding motif is able to interact with Mef2 and activate transcription through a subset of Mef2-dependent regulatory elements in the heart. 8 Recently, it was reported that Myocd overexpression could directly convert human endothelial progenitor cells to induced smooth muscle cells (iSMCs). 9 For clinical purposes, identifying transcription factors that could directly reprogram SMCs from fibroblast is highly significant. For instance, in the aorta, endothelial dysfunction and inflammation induce dysregulated expansion of the myofibroblast (activated fibroblasts) population. Although the results here may not directly translate to leverage resident myofibroblasts for treatment, the present studies on direct reprogramming of fibroblasts into SMC is an encouraging step toward that next frontier. 10, 11 In this study, we used mouse embryonic fibroblasts (MEFs) to screen various combinations of transcription factors, such as Myocd, Mef2C, Mef2B (myocyte enhancer factor 2C), Mkl1, Gata4, Gata5, Gata6, Ets1 (E26 avian leukemia oncogene 1, 5' domain), and the carboxy-terminus fusion genes of Myocd, Mef2C, Mef2B, and Mkl1 with the transactivation domain of MyoD (myogenic differentiation 1), to facilitate epigenetic remodeling of chromatin 12, 13 (Myocd*, Mef2C*, Mef2B*, and Mkl1*). After systematic testing of groupings, we successfully identified multiple combinations of transcription factors able to promote fibroblast-to-iSMC differentiation. We demonstrated that the combination of transcription factors Myocd*, Gata6, and Mef2C* (M*G2*) could sufficiently and efficiently activate smooth muscle-specific Myh11 (myosin heavy polypeptide 11) and downregulate fibroblast markers. The main findings were replicated in human dermal fibroblasts, with Myocd, Gata6, and Mef2C* (MG2*) efficiently rendering hiSMCs in this system.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Preparation of Mouse Fibroblast Cells and Vascular SMCs
MEFs were prepared from E13.5 embryos of the C57BL/6 mice as reported previously. 12 Vascular SMCs were isolated from 15-week C57BL/6 mice as reported previously.
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Generation of iSMCs
Mouse iSMC
The mouse MyoD M3 domain (amino acids 1-62) was fused to full-length cDNAs encoding mouse Myocd (kind gift of Dr Olson), 8 Mef2B, Mef2C, and Mkl1 at the carboxy-terminus to create the fusion genes Myocd*, Mef2B*, Mef2C*, and Mkl1*. pMXs-IP (kind gift of Dr Kitamura) 15, 16 vectors encoding the fusion genes and wildtype genes Myocd, Mef2B, Mef2C, Mkl1, Ets1, Gata4, and Gata6, as well as the empty vector virus control, were separately transfected into Plat-E cells (kind gift of Dr Kitamura) 17 with Lipofectamine 2000 (Thermo Fisher Scientific). The supernatants containing retroviruses encoding these genes were harvested after 48 hours (called day 1) as described previously, 18 filtered through a 0.45-μm syringe filter. Titration of retrovirus was performed using the Retro-X qRT-PCR Titration Kit (Takara Bio) according to the manufacturer's protocol. The differentiation protocol is summarized in Figure 1A . On day 2, MEFs were seeded at a density of 2.5×10 3 cells per cm 2 in each well of 48-well or 24-well plates in fibroblast medium containing DMEM, 10% fetal bovine serum, and penicillin-streptomycin (Thermo Fisher Scientific) for the virus transduction. Various combinations of fresh 0.3 mL of virus supernatant (include 2.5×10 9 ±0.2 copies) were added to 1.0×10 4 MEF on day 1 with 10 μg/mL polybrene. The virus supernatant was changed to fibroblast medium on day 0. On day 1, the mouse fibroblast medium was changed to SMC medium containing DMEM/nutrient mixture F-12 (DMEM/F-12), 10% knockout serum replacement, 2 ng/mL recombinant human TGF-β1 (transforming growth factor beta 1; PeproTech), 10 ng/mL human PDGF-BB (platelet derived growth factor-BB; Shenandoah Biotechnology), and 1% penicillin-streptomycin, which was replaced every other day thereafter ( Figure 1A ). 2 in each well of 48-well, or 24-well plates in human fibroblast medium containing DMEM/F-12, 10% fetal bovine serum, and penicillin-streptomycin (Thermo Fisher Scientific) for the virus transduction. Various combinations of fresh 0.3 mL of virus supernatant were added to hFB on day −1 with 10 μg/mL polybrene. The virus supernatant was changed to fibroblast medium on day 0. On day 1, the human fibroblast medium was changed to SMC medium containing DMEM/F-12, 10% knockout serum replacement, 2 ng/mL recombinant human TGF-β1, 10 ng/mL human PDGF-BB, and 1% penicillin-streptomycin, which was replaced every other day thereafter ( Figure 1A ).
Human iSMC
Immunofluorescence Staining and Time-Lapse Image Acquisition
Cells were fixed with 4% formaldehyde in PBS for 10 minutes and permeabilized with 0.5% Triton X-100 in PBS. Cells were stained with the primary and secondary antibodies for 1 hour each at room temperature. The following primary antibodies against myosin-11 (Abcam), Cnn1 (Calponin1; Sigma-Aldrich), α-SMA (α-smooth muscle actin; Sigma-Aldrich) and secondary antibodies either antirabbit IgG (H+L) or anti-mouse IgG (H+L) conjugated to Alexa Fluor 488 (Thermo Fisher Scientific) were used. Nuclei were counterstained with DAPI. Percentage of cells positive for Myosin-11, Cnn1, and α-SMA was obtained from 3 independent experiments. Two hundred of cells were counted in each experiment. Fluorescence and time-lapse images were obtained with an OLYMPUS microscope as described below and processed with Adobe Photoshop CS6 and Adobe Illustrator CS6 (Adobe Systems). Carbachol-induced contractility assay was performed as described previously. 19, 20 Briefly, phase-contrast time lapse of carbachol (100 µmol/L, Alfa Aesar)-induced contraction of iSMC was recorded with a DP70 microscope digital camera with an IX71 phase-contrast fluorescent motorized inverted microscope using DP Controller and edited with DP Manager (Olympus) in a time-lapse manner at 1-minute intervals for 30 minutes. Contraction was determined by tracking individual cells in the videos.
Real-Time Quantitative ReverseTranscription Polymerase Chain Reaction
Total RNA was purified from cells and from 5-week-old mouse aorta media and heart with a Direct-zol RNA MicroPrep (Zymo Research) and treated with DNase I as directed by the manufacturer. cDNA was synthesized using a SuperScript IV First-Strand Synthesis System (Thermo Fisher Scientific) and quantitative reverse-transcription polymerase chain reaction was performed with iTaq universal SYBR Green supermix (Bio-Rad Laboratories) on a Realplex 2S system (Eppendorf). The mRNA level was normalized with that of 18S ribosomal RNA. The SEM was calculated from the values obtained from 3 independent experiments. Aorta media was used as a positive control. Please see Table I in the online-only Data Supplement for the list of primers used. 
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Statistical Analysis
Data are expressed as mean±SEM. Analyses were performed using SPSS 24.0 (SPSS, Chicago, IL). All data were tested for normality and equal variance. If the data passed the normality and equal variance tests, Student t test was used to compare 2 groups or 1-way ANOVA followed by Tukey post hoc for comparisons among >2 groups. If the data did not pass the normality or equal variance test, nonparametric tests (Mann-Whitney U and Kruskall-Wallis tests) were used. A P value <0.05 was considered statistically significant.
Results
Because Myocd controls SMC gene expression and smooth muscle development, [1] [2] [3] [4] [5] we first tested the ability of Myocd to activate endogenous SMC-specific gene expression by itself or in combination with other factors following the protocol outlined in Figure 1A . To determine the effects of Myocd on SMC reprogramming, we transduced MEF cells with retrovirus carrying Myocd in SMC culture medium. Myh11, Acta2 (actin), Cnn1, SmthB, and Tagln (transgelin [SM22-α]) gene expression was used to assess the quality of induced iSMC. Consistent with previous reports, [1] [2] [3] [4] [5] Myocd induced endogenous SMC-specific markers, such as Myh11, Acta2, Cnn1, Smtn-B (smoothelin b), and Tagln in MEFs ( Figure I in the online-only Data Supplement). Except for Myh11 and endogenous Myocd, the expression level of other SMC genes tested was similar to those of aorta media ( Figure I in the onlineonly Data Supplement). We noticed that Myh11 expression level is >3-fold lower compared with aorta media, even when Myocd expression levels were 3-fold higher than in aorta media ( Figure I in the online-only Data Supplement). Interestingly, similar level of Myocd expression to that of aorta media induces <20% Myh11 expression compared with that in aorta media and even 4× higher Myocd still fails to induce Myh11 to aorta media levels ( Figure I in the onlineonly Data Supplement). Aorta media was used as a positive control because the expression level of Myh11-the most stringent smooth muscle marker-is expected to represent that in vivo, whereas primary vascular SMCs in culture consistently showed >200-fold lower levels than aorta media for this gene ( Figure II in the online-only Data Supplement).
To search for an optimal combination of transcription factors capable of inducing smooth muscle lineage reprogramming, we generated retroviruses to express each of the 7 core smooth muscle and cardiac transcription factors Myocd*, Mef2B, Mef2B*, Mkl1, Mkl1*, Gata4 (GATA-binding protein 4), and Ets1 in MEFs ( Figure III in the online-only Data Supplement). In the first round of screening, the cocktail of 4 genes, Myocd*, Mkl1, Mef2B, Gata4, was the most effective. The results suggest that, in the absence of Gata4, Mef2B* is better than Mef2B for Cnn1 induction. The positive effects of Gata4, such as activation of Tagln gene expression, were unexpected because former studies showed that GATA4 can repress the Myocd-induced Tagln promoter activation in A10 SMCs. 21 Yet, our results indicate that the combination of transcription factors tested here could activate smooth muscle genes, including Tagln. When the MyoD activation domain was fused with Mkl1, that is in Mlk1*, the fusion gene was inhibitory for induction of smooth muscle genes. We then compared the combination of 4 genes and found that, indeed, Mkl1 was not required for the induction of smooth muscle genes ( Figure  IVA in the online-only Data Supplement). Myocd*, Mef2B*, and Gata4 was the most effective combination of 3 genes in this first round. The 3 genes induced Myh11 expression in MEFs efficiently and >3-fold higher than the Myocd* alone as of day 10 ( Figure IVB in the online-only Data Supplement). We considered the possibility that other isoform of Mef2, Mef2C, might promote SMC reprogramming. To test this, we compared Mef2B* and Mef2C* ( Figure 1B ; Figure IVB in the online-only Data Supplement). Myh11 reached a peak of expression on day 5 post-transduction. To our surprise, Mef2B* and Mef2C* had similar effect on Myh11 expression. There was no significant difference beyond a slight but reproducible increase in Myh11 induction in the combination of Myocd* with Mef2C* and Gata4 compared with Myocd* with Mef2B* and Gata4 on days 5 and 10. Next, we used the combination of Myocd* with Mef2C* and Gata4 for further validation. Myh11 expression was consistently more efficient on day 5 than day 3 or 4 with Myocd* with Mef2C* and Gata4 ( Figure 1C ). Smooth muscle-specific genes were efficiently induced when cultured with SMC culture medium but not fibroblast medium ( Figure V in the online-only Data Supplement). We also addressed whether other members of the Gata family could improve MEF differentiation into iSMCs by quantitative reverse-transcription polymerase chain reaction analysis of gene expression patterns in iSMCs to ascertain the increased expression of smooth muscle-specific genes and concomitant suppression of fibroblast-specific markers. Indeed, former studies showed that Gata6 and Myocd synergistically activate the promoter of smooth muscle myosin heavy chain in A10 SMCs, 21 whereas in 10T1/2 fibroblast cells, overexpression of smooth muscle differentiation factor Gata6 22 was not able to induce the expression of endogenous smooth muscle genes, suggesting that Gata6 alone is not sufficient to drive fibroblast cells to differentiate into SMCs. 21 Based on these data, we verified that the gene expression pattern of SMC markers was optimized compared with Myocd alone through our protocol of reprogramming from MEFs. We see similar trends in the combination of Myocd*/Myocd with Mef2C*/C and Gata4/5/6 genes ( Figure 1D ; Figures IVB, VIA, and VIB in the online-only Data Supplement). Myocd induces smooth muscle target genes but does not repress fibroblast markers in MEFs efficiently in this context ( Figure VIC in the online-only Data Supplement). Thus, compared with the other combinations tested, such as Myocd* with Mef2C* and Gata5/6 or Myocd with Mef2C and Gata4/5/6, the combination of the 3 factors Myocd*, Mef2C*, and Gata6 was the most effective in overall suppression of the fibroblast-specific genes ( Figure 1D ; Figure VIB in the online-only Data Supplement) while inducing Myh11 to levels comparable with Gata4 ( Figure 1C ; Figure VIA in the online-only Data Supplement). Furthermore, iSMCs derived from transduction of Myocd* in combination with Mef2C* and Gata6 showed smooth musclespecific genes significantly upregulated when compared with empty vector virus control, with expression patterns similar to those in the aorta media control (Figure 2A ). In addition to the 4 maturation-related markers, we verified the upregulation of endogenous Myocd and Col3a1 and Smtn-B and confirmed the downregulation of fibroblast-enriched genes, specifically Fn-EDA, Thy1, Snai1, and Snai2, in those iSMCs (Figure 2A and 2B; Figure VIIA in the online-only Data Supplement). KLF4 and KLF5 are negative regulators of Myocd transcription in mice and rats. [23] [24] [25] To address whether they might be responsible for a potential feedback repression of endogenous Myocd, we determined their expression levels in our experimental conditions and found that they were unresponsive to our differentiation protocol ( Figure VIIA in the online-only Data Supplement). Additionally, there was no induction of cardiac genes at day 10 post-transduction ( Figure VIIB in the online-only Data Supplement), indicating that in these conditions, iSMCs acquire maturity similar to that of the aorta media. Immunofluorescent staining of iSMCs showed expression of SMC markers Cnn1 and α-SMA ( Figure VIIIA through VIIIC in the online-only Data Supplement) and further demonstrated that 93% of iSMCs were positively stained for the most specific SMC marker, myosin-11 ( Figure 2C and  2D, left) , and the contractile function was confirmed by treatment with carbachol 26 (Figure 2E , top; Figure IX in the onlineonly Data Supplement; Movies I through IV in the online-only Data Supplement). Taken together, these results indicate that the combination of Myocd*, Mef2C*, and Gata6 can induce smooth muscle gene expression in MEFs better than the other combinations tested in this approach. We additionally compared the combination of Myocd*, Gata6, and Mef2C* with Myocd, Gata6, and Mef2C* for the induction of smooth muscle marker genes and fibroblast marker genes ( Figure XA and XB in the online-only Data Supplement). There was no significant difference in induction of smooth muscle and repression of fibroblast marker genes or in Klf4 and Klf5 expression between the combination of Myocd*, Gata6, and Mef2C* versus Myocd, Gata6, and Mef2C*, indicating that both Myocd* and Myocd are equally effective. Finally, we applied MYOCD with GATA6 and MEF2C* for the reprogramming of human iSMCs from hFBs. MG2* induced MYH11 to aorta media levels and the other SMC markers above aorta media levels ( Figure XIA in the onlineonly Data Supplement). Interestingly, in contrast to MEFs, in human fibroblasts, the 3 factors could not induce endogenous MYOCD ( Figure XIA in the online-only Data Supplement). Indeed, in human dermal fibroblasts, MYOCD basal expression was at the same level as in aorta media, whereas MYH11 was 1000-fold lower. Regulation of MYOCD is not well characterized in human compared with animal models.
27 KLF4 and KLF5 bind to the MYOCD promoter regions and mediate transcriptional repression in humans as well. 27, 28 KLF4 and KLF5 were highly expressed in aorta media compared with fibroblasts ( Figure XIA in the online-only Data Supplement). On the contrary, in hiSMCs, KLF5 was expressed at a higher level than in fibroblasts and aorta media ( Figure XIA in the online-only Data Supplement), suggesting that KLF5 might be responsible for the apparent repression of endogenous MYOCD in hiSMCs. More importantly, it is apparent that in hFBs, our MG2* was able to effectively and remarkably repress fibroblast genes, including SNAI1, SNAI2, and THY1, to aorta media levels, unlike in MEFs ( Figure 
Discussion
Elucidation of the regulatory mechanisms driving and controlling developmental programs of fate decisions toward SMC lineage and differentiation is fundamental and clinically important in the study of vascular diseases. In this study, we report a novel combination of transcription factors coupled with forward reprogramming to significantly improve the expression of Myh11 from fibroblasts. We found a combination of 3 transcription factors, Myocd*, Mef2C*, and Gata6, that facilitate direct reprogramming of MEFs to smooth muscle-like cells, iSMCs. We demonstrated that in addition to enhancing the overall expression of Myh11 ( Figure 1C ), the combination of those specific transcription factors, namely Myocd* (or Myocd), Mef2C*, and Gata6, could enhance the maturation of iSMC by reducing fibroblast-specific gene expression ( Figure 2B ; Figure  X in the online-only Data Supplement). Indeed, Myh11 levels in iSMC were comparable with those of aorta media (Figure 2A ) with >90% of the cells expressing myosin-11-a marker for terminally differentiated SMCs ( Figure 2C and 2D) . It is noted that reduction of fibroblast-specific genes is still insufficient. Furthermore, we were able to reprogram hFBs using the Myocd, Mef2C*, and Gata6 combination, which rendered 80% of the cells expressing myosin-11 ( Figure 2C and 2D) , with remarkable reduction in fibroblast markers in this case ( Figure XIB in the online-only Data Supplement). Induction of endogenous Myocd does not achieve the same levels as the corresponding tissue aorta media ( Figure VII and XI in the online-only Data Supplement). Our findings point to a complex regulation of MYOCD in human aorta, which is beyond the scope of this brief report but merits further investigation. Our results suggest the existence of MYOCD-independent MYH11 induction in human aorta media. Conversely, it is also possible that in human dermal fibroblasts, there is active repression of MYH11, overcoming any effects of basal levels of MYOCD in those cells. Understanding the complexity of such interplay will require further systematic dissection of MYOCD expression and function in human aorta, as well as any potential differences between embryonic and adult fibroblasts and potential epigenetic modification. 29, 30 Therefore, it should be assumed that these iSMCs represent partially reprogrammed smooth muscle-like cells. Furthermore, the direct reprogramming requires resetting of the epigenetic memory of the parent cells. Combining small-molecule epigenetic modulators and modified transcription factors within effective time windows 31 could improve the generation of mature iSMCs by facilitating epigenetic reprogramming.
Although further improvements to the protocol will still be necessary to increase the population of mature SMCs through direct reprogramming of fibroblasts, forward reprogramming toward of the smooth muscle lineage holds great promise for the field of aorta vascular regeneration by providing the tools to generate new SMCs from differentiated adult cells, as for instance, resident myofibroblasts. Induced cells could be considered as a potential cell source for regeneration therapy for cardiovascular diseases. Furthermore, it is hoped that induced patient-specific SMCs will become experimental platforms to investigate cardiovascular disease in the context of personalized medicine. Except in Alzheimer disease in which increases in SMC contractile proteins are associated with the disorder, 16 most vascular diseases correlate with a decrease in SMC contractile proteins. Based on these findings, the identification of functional differences caused by various vascular diseases and differences in gene expression between diseased SMC and normal SMC would be important for preclinical applications of this approach.
